Composition and methods for treatment or prophylaxis of coronavirus and cancers
AssigneeBetahealth LLC
InventorPablo Antonio Betancourt
Life of this patent
Estimating the term…
Abstract
Described herein is a composition and methods for treating, reducing the symptoms of, or prophylaxis of viral infections, and particularly SARS-CoV-2. The composition enhances delivery of oxygen to the tissues. Also described herein is a composition and methods for treating cancers, particularly, adenocarcinomas, infiltrating ductal adenocarcinoma, metastatic ductal adenocarcinoma, and neuroendocrine tumors. The composition inhibits the growth of tumor cells and promotes cytoreduction of tumors.
Claims20
A method for treating or reducing the symptoms of a coronavirus, the method comprising administering by injection a therapeutically effective amount of a liquid pharmaceutical composition comprising:
- about 0.1-0.3 mg/mL procaine;
- about 1-3 mg/ml of a tri- or tetra-peptide comprising one or more glutamate residues or a pharmaceutically acceptable salt thereof;
- and about 0.0008-0.0012 mg/mL DNase 1 to a subject in need thereof, wherein 1000 IU (10 mL) per day of the pharmaceutical composition are administered to the subject in need thereof.
A method for increasing the SpO2 of a subject suffering from a coronavirus, the method comprising administering by injection a therapeutically effective dose of a pharmaceutical composition comprising about 0.1-0.3 mg/mL procaine;
- about 1-3 mg/ml of a tri-or tetra-peptide comprising one or more glutamate residues or a pharmaceutically acceptable salt thereof;
- and about 0.0008-0.0012 mg/ml DNase 1 to a subject in need thereof, wherein 1000 IU (10 mL) per day of the pharmaceutical composition are administered to the subject in need thereof.
A method for preventing infection with a coronavirus, the method comprising administering a therapeutically effective amount of a liquid pharmaceutical composition comprising:
- about 0.1-0.3 mg/ml procaine;
- about 1-3 mg/mL of a tri-or tetra-peptide comprising one or more glutamate residues or a pharmaceutically acceptable salt thereof;
- and about 0.0008-0.0012 mg/mL DNase 1 to a subject in need thereof, wherein 100 IU (1 mL) per day of the pharmaceutical composition are administered to the subject in need thereof.
Dependencies are inferred from the claim text.